| Literature DB >> 33860831 |
Stefan Pszczolkowski1,2, José P Manzano-Patrón3, Zhe K Law4,5, Kailash Krishnan6, Azlinawati Ali4, Philip M Bath4,6, Nikola Sprigg4,6, Rob A Dineen3,7,8.
Abstract
OBJECTIVES: To test radiomics-based features extracted from noncontrast CT of patients with spontaneous intracerebral haemorrhage for prediction of haematoma expansion and poor functional outcome and compare them with radiological signs and clinical factors.Entities:
Keywords: Cerebral parenchymal hemorrhage; Linear models; Predictive medicine; Radiomics
Mesh:
Year: 2021 PMID: 33860831 PMCID: PMC8452575 DOI: 10.1007/s00330-021-07826-9
Source DB: PubMed Journal: Eur Radiol ISSN: 0938-7994 Impact factor: 5.315
Fig. 1Study inclusion flowchart
Fig. 2Feature extraction process flowchart. NCCT scans and their annotations are resampled to 1mm isotropic. Shape features are extracted from the resampled annotations and intensity and texture features are extracted from the resampled original and filtered images. This set of features, together with ultra-early haematoma growth are harmonised and the final set of uncorrelated features is then computed using a correlation-based filtering method. NCCT, noncontrast computed tomography; LoG, Laplacian of Gaussian
Fig. 3Training and testing procedure. The training UK data is split into 10 non-overlapping folds and 10 different models are trained for each value of the hyperparameter α, using each fold as validation data once. The model that shows the greatest AUC is selected for testing using the non-UK holdout data
Patient characteristics for the training and testing datasets with respect to haematoma expansion. Data are number (%), mean (SD), or median (IQR). ‡p value between testing and training datasets
| Testing dataset ( | Training dataset ( | ||||||
|---|---|---|---|---|---|---|---|
| Haematoma expansion | No haematoma expansion | Haematoma expansion | No haematoma expansion | ||||
| Number | 137 (26.3%) | 384 (73.7%) | 337 (27.8%) | 874 (72.2%) | |||
| Age, years | 70.03 (13.13) | 68.52 (12.95) | .244 | 69.94 (14.26) | 68.39 (13.72) | .082 | .894 |
| Gender, male | 82 (59.9%) | 211 (54.9%) | .367 | 200 (59.3%) | 481 (55.0%) | .196 | .999 |
| Treatment allocation, placebo | 77 (56.2%) | 185 (48.2%) | .112 | 183 (54.3%) | 424 (48.5%) | .073 | .950 |
| Baseline volume, mL | 20.88 (7.73–40.00) | 10.09 (5.12–20.65) | < .001 | 20.84 (7.50–42.98) | 10.15 (4.68–20.52) | < .001 | .851 |
| Onset to CT scan, h | 1.73 (1.30–2.51) | 2.03 (1.40–3.13) | .004 | 1.80 (1.27– 2.47) | 2.00 (1.38–3.00) | < .001 | .564 |
| Ultra-early haematoma growth, mL/h | 11.06 (4.74–22.37) | 5.12 (2.25–10.77) | < .001 | 10.81 (4.32–23.40) | 5.04 (2.10–11.68) | < .001 | .887 |
| Systolic blood pressure, mm Hg | 172.01 (30.32) | 174.25 (28.78) | .440 | 173.73 (28.58) | 176.26 (29.66) | .181 | .218 |
| Previous antiplatelet therapy | 39 (28.5%) | 92 (24.0%) | .304 | 98 (29.1%) | 194 (22.2%) | .013 | .647 |
| Blend sign, present | 33 (24.1%) | 48 (12.5%) | .002 | 79 (23.4%) | 89 (10.2%) | < .001 | .362 |
| Black hole sign, present | 30 (21.9%) | 49 (12.8%) | .013 | 77 (22.8%) | 133 (15.2%) | .002 | .265 |
| Hypodensities, present | 50 (36.5%) | 84 (21.9%) | .001 | 134 (39.8%) | 209 (23.9%) | < .001 | .266 |
| Island sign, present | 16 (11.7%) | 19 (4.9%) | .010 | 37 (11.0%) | 51 (5.8%) | .003 | .683 |
Patient characteristics for the training and testing datasets with respect to functional outcome. Data are number (%), mean (SD), or median (IQR). ‡p value between testing and training datasets
| Testing dataset ( | Training dataset ( | ||||||
|---|---|---|---|---|---|---|---|
| Poor functional outcome | Good functional outcome | Poor functional outcome | Good functional outcome | ||||
| Number | 258 (49.9%) | 259 (50.1%) | 643 (53.5%) | 559 (46.5%) | |||
| Age, years | 72.55 (12.30) | 65.29 (12.75) | < .001 | 73.10 (12.80) | 64.08 (13.52) | < .001 | .989 |
| Gender, male | 128 (49.6%) | 164 (63.3%) | .002 | 319 (49.6%) | 353 (63.1%) | < .001 | .826 |
| Treatment allocation, placebo | 130 (50.4%) | 129 (49.8%) | .930 | 320 (49.8%) | 283 (50.6%) | .773 | .979 |
| Baseline volume, mL | 20.20 (9.79–40.49) | 7.27 (3.51–14.51) | < .001 | 18.78 (7.71–42.14) | 7.50 (3.36–14.83) | < .001 | .869 |
| Onset to CT scan, hours | 1.89 (1.33– 2.93) | 2.00 (1.38– 3.05) | .387 | 1.92 (1.33– 2.75) | 1.95 (1.37– 2.83) | .178 | .497 |
| Ultra-early haematoma growth, mL/h | 10.40 (4.78–20.98) | 4.09 (1.52–7.39) | < .001 | 9.65 (4.04–22.61) | 3.58 (1.62–8.06) | < .001 | .865 |
| Systolic blood pressure, mm Hg | 172.26 (28.63) | 174.84 (29.81) | .316 | 174.93 (29.14) | 176.08 (29.24) | .497 | .214 |
| Previous antiplatelet therapy | 79 (30.6%) | 52 (20.1%) | .006 | 195 (30.3%) | 97 (17.4%) | < .001 | .644 |
| Blend sign, present | 49 (19.0%) | 31 (12.0%) | .029 | 105 (16.3%) | 62 (11.1%) | .009 | .392 |
| Black hole sign, present | 51 (19.8%) | 27 (10.4%) | .003 | 147 (22.9%) | 61 (10.9%) | < .001 | .258 |
| Hypodensities, present | 87 (33.7%) | 46 (17.8%) | < .001 | 233 (36.2%) | 107 (19.1%) | < .001 | .276 |
| Island sign, present | 32 (12.4%) | 3 (1.2%) | < .001 | 79 (12.3%) | 9 (1.6%) | < .001 | .684 |
Fig. 4TSNE visualisations of standardised training and testing radiomics feature vectors for each of the 3 harmonisation batches. Each point represents a feature vector for one subject. The left column corresponds to subject radiomics feature vectors pre-harmonisation and the right column corresponds to subject radiomics feature vectors post-harmonisation
Fig. 5Threshold analysis for sensitivity, specificity, Youden’s index, F1 score, F0.5 score, and F2 score (left column) and ROC curve (right column) for the five prediction models of haematoma expansion (radiomics, radiological signs, radiomics and signs combined, clinical factors, and radiomics and clinical factors combined). Optimal threshold criterion was maximal Youden’s index
Fig. 6Threshold analysis for sensitivity, specificity, Youden’s index, F1 score, F0.5 score, and F2 score (left column) and ROC curve (right column) for the three prediction models of poor functional (radiomics, radiological signs, radiomics and signs combined, clinical factors, and radiomics and clinical factors combined). Optimal threshold criterion was maximal Youden’s index
Performance table of all models, both on the testing and training sets. NCCT, noncontrast computed tomography; AUC, area under the receiver operating characteristic curve; PPV, positive predictive value; NPV, negative predictive value
| Testing dataset | Training dataset | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Threshold | AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Prevalence (95% CI) | AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Prevalence (95% CI) | ||
| Haematoma expansion | NCCT radiomics | 0.2986 | 0.693 (0.638–0.747) | 0.635 (0.554–0.716) | 0.690 (0.644–0.736) | 0.422 (0.355–0.49) | 0.841 (0.801–0.882) | 0.263 (0.225–0.301) | 0.681 (0.646–0.716) | 0.602 (0.550–0.655) | 0.672 (0.640–0.703) | 0.414 (0.371–0.458) | 0.814 (0.786–0.843) | 0.278 (0.253–0.304) |
| Radiological signs | 0.2793 | 0.609 (0.552–0.665) | 0.467 (0.384–0.551) | 0.711 (0.666–0.756) | 0.366 (0.294–0.437) | 0.789 (0.746–0.832) | 0.263 (0.225–0.301) | 0.620 (0.584–0.656) | 0.507 (0.454–0.561) | 0.700 (0.670–0.731) | 0.395 (0.349–0.441) | 0.787 (0.758–0.815) | 0.278 (0.253–0.304) | |
| NCCT radiomics + radiological signs | 0.2986 | 0.693 (0.638–0.747) | 0.635 (0.554–0.716) | 0.69 (0.644–0.736) | 0.422 (0.355–0.49) | 0.841 (0.801–0.882) | 0.263 (0.225–0.301) | 0.681 (0.646–0.716) | 0.602 (0.550–0.655) | 0.672 (0.640–0.703) | 0.414 (0.371–0.458) | 0.814 (0.786–0.843) | 0.278 (0.253–0.304) | |
| Clinical factors | 0.3101 | 0.668 (0.613–0.723) | 0.350 (0.270–0.430) | 0.839 (0.802–0.875) | 0.436 (0.344–0.529) | 0.783 (0.744–0.823) | 0.263 (0.225–0.301) | 0.637 (0.601–0.673) | 0.368 (0.316–0.419) | 0.835 (0.811–0.86) | 0.463 (0.403–0.522) | 0.774 (0.747–0.801) | 0.278 (0.253–0.304) | |
| NCCT radiomics + clinical factors | 0.3073 | 0.704 (0.651–0.758) | 0.650 (0.570–0.730) | 0.711 (0.666–0.756) | 0.445 (0.376–0.514) | 0.85 (0.811–0.889) | 0.263 (0.225–0.301) | 0.690 (0.655–0.725) | 0.588 (0.535–0.640) | 0.706 (0.676–0.736) | 0.435 (0.390–0.481) | 0.816 (0.789–0.844) | 0.278 (0.253–0.304) | |
| Poor functional outcome | NCCT radiomics | 0.6035 | 0.783 (0.744–0.823) | 0.698 (0.642–0.754) | 0.741 (0.688–0.795) | 0.729 (0.673–0.784) | 0.711 (0.657–0.765) | 0.499 (0.456–0.542) | 0.814 (0.790–0.834) | 0.644 (0.607–0.681) | 0.844 (0.814–0.874) | 0.826 (0.793–0.860) | 0.673 (0.639–0.708) | 0.535 (0.507–0.563) |
| Radiological signs | 0.5911 | 0.621 (0.573–0.669) | 0.318 (0.261–0.375) | 0.880 (0.841–0.920) | 0.726 (0.643–0.808) | 0.564 (0.516–0.613) | 0.499 (0.456–0.542) | 0.612 (0.580–0.643) | 0.327 (0.290–0.363) | 0.864 (0.836–0.892) | 0.734 (0.683–0.785) | 0.527 (0.495–0.560) | 0.535 0.507–0.563) | |
| NCCT radiomics + radiological signs | 0.6035 | 0.783 (0.744–0.823) | 0.698 (0.642–0.754) | 0.741 (0.688–0.795) | 0.729 (0.673–0.784) | 0.711 (0.657–0.765) | 0.499 (0.456–0.542) | 0.814 (0.790–0.834) | 0.644 (0.607–0.681) | 0.844 (0.814–0.874) | 0.826 (0.793–0.860) | 0.673 (0.639–0.708) | 0.535 (0.507–0.563) | |
| Clinical factors | 0.5845 | 0.789 (0.750–0.828) | 0.620 (0.561–0.679) | 0.815 (0.767–0.862) | 0.769 (0.712–0.826) | 0.683 (0.631–0.735) | 0.499 (0.456–0.542) | 0.777 (0.751–0.803) | 0.596 (0.558–0.634) | 0.818 (0.786–0.850) | 0.790 (0.753–0.826) | 0.637 (0.602–0.673) | 0.535 (0.507–0.563) | |
| NCCT radiomics + clinical factors | 0.6094 | 0.818 (0.781–0.854) | 0.694 (0.638–0.750) | 0.826 (0.780–0.872) | 0.799 (0.747–0.852) | 0.730 (0.68–0.781) | 0.499 (0.456–0.542) | 0.835 (0.813–0.858) | 0.663 (0.626–0.699) | 0.852 (0.822–0.881) | 0.837 (0.805–0.869) | 0.687 (0.652–0.721) | 0.535 (0.507–0.563) | |
Ranking of radiomics-based features selected in elastic-net training in terms of their importance. Only features with an importance greater than 1% are shown. Standardised model coefficients are also provided in boldface (positive) and italics (negative)
| Haematoma expansion | Poor functional outcome | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCCT features | NCCT features + clinical factors | NCCT features | NCCT features + clinical factors | |||||||||
| Feature name | Model coefficient | Importance percentage | Feature name | Model coefficient | Importance percentage | Feature name | Model coefficient | Importance percentage | Feature name | Model coefficient | Importance percentage | |
| (Intercept) | - | (Intercept) | - | (Intercept) | - | (Intercept) | - | |||||
| 1 | LoG-35 interquartile range | 45.9% | LoG-35 interquartile range | 38.1% | Perihaematomal oedema volume | 8.0% | Age | 20.5% | ||||
| 2 | LoG-15 GLSZM grey level non-uniformity | 16.3% | Intensities GLSZM small zone emphasis | 14.6% | LoG-35 variance | 7.7% | LoG-35 variance | 10.5% | ||||
| 3 | Intensities GLSZM small zone emphasis | 15.3% | Onset to CT scan | 12.7% | Wavelet-HHH mean | 6.9% | Ultra-early haematoma growth | 8.3% | ||||
| 4 | Intracerebral haemorrhage major axis length | 10.4% | LoG-15 GLSZM grey level non-uniformity | 12.4% | Wavelet-LLL mean | 6.8% | Perihaematomal oedema volume | 5.3% | ||||
| 5 | LoG-25 mean absolute deviation | 4.8% | Intracerebral haemorrhage major axis length | 8.3% | Wavelet-HHH kurtosis | 5.9% | Wavelet-HHH kurtosis | − | 5.0% | |||
| 6 | LoG-25 kurtosis | 4.8% | LoG-25 kurtosis | 6.3% | Intracerebral haemorrhage sphericity | 5.7% | LoG-25 GLSZM grey level non-uniformity | 4.0% | ||||
| 7 | Intensities 10th percentile | 2.6% | Intensities 10th percentile | 4.2% | Intraventricular haemorrhage volume | 5.0% | Intensities 10th percentile | − | 3.9% | |||
| 8 | LoG-25 mean absolute deviation | 3.0% | LoG-25 GLSZM grey level non-uniformity | 4.7% | Intraventricular haemorrhage volume | 3.8% | ||||||
| 9 | Intracerebral haemorrhage flatness | 4.2% | Wavelet-HHH mean | 3.2% | ||||||||
| 10 | Wavelet-LLH energy | 4.1% | LoG-15 GLRLM long run low grey level emphasis | 3.1% | ||||||||
| 11 | LoG-05 GLSZM grey level variance | 3.8% | Intracerebral haemorrhage flatness | 3.0% | ||||||||
| 12 | Wavelet-HHL energy | 3.7% | Intracerebral haemorrhage sphericity | 2.8% | ||||||||
| 13 | Wavelet-LHL GLCM dissimilarity | 3.6% | LoG-05 GLSZM grey level variance | 2.7% | ||||||||
| 14 | Wavelet-LLL GLRLM long run low grey level emphasis | 3.6% | Wavelet-LLL GLRLM long run low grey level emphasis | 2.7% | ||||||||
| 15 | Wavelet-LHL median | 3.2% | Wavelet-LLH GLRLM long run low grey level emphasis | 2.7% | ||||||||
| 16 | LoG-15 GLRLM long run low grey level emphasis | 2.0% | Wavelet-HHH NGTDM complexity | 2.3% | ||||||||
| 17 | Wavelet-HHH NGTDM complexity | 1.5% | LoG-35 GLSZM small zone low grey level emphasis | 1.9% | ||||||||
| 18 | Wavelet-LHH median | 1.4% | Wavelet-LHL GLCM dissimilarity | 1.8% | ||||||||
| 19 | Wavelet-HHL maximum | 1.3% | LoG-35 NGTDM complexity | 1.6% | ||||||||
| 20 | Wavelet-LLH GLCM entropy | 1.3% | Wavelet-LHL GLSZM small zone high grey level emphasis | 1.6% | ||||||||
| 21 | Wavelet-HHH minimum | 1.2% | Wavelet-HHL GLRLM long run low grey level emphasis | 1.6% | ||||||||
| 22 | Wavelet-HHL GLRLM long run low grey level emphasis | 1.2% | Wavelet-LHL median | 1.5% | ||||||||
| 23 | Wavelet-LLL minimum | 1.1% | Wavelet-LLL GLRLM run length variance | 1.3% | ||||||||
| 24 | LoG-35 NGTDM complexity | 1.0% | Wavelet-LLL minimum | 1.2% | ||||||||
| 25 | Wavelet-LHL GLSZM small zone high grey level emphasis | 1.0% | ||||||||||